Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killi

Trial Details

NCT ID
NCT04871607
Phase
PHASE2
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Basiliximab
  • Carmustine
  • Cytarabine
  • Etoposide
  • Genetically Engineered Hematopoietic Stem Progenitor Cells
  • Recombinant Granulocyte Colony-Stimulating Factor
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

  • \- Assent, when appropriate, will be obtained per institutional guidelines Age Criteria, Performance status
  • Age: ≥18 years
  • Karnofsky performance status ≥ 70%
  • Life expectancy ≥ 6 months Nature of Illness and Illness Related Criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →